Goldman Sachs Group Inc Leap Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	BUY	$0.92 - $9.3 $263 - $2,659	286 Added 0.86%	33,352 $29,000
Q3 2022 Nov 10, 2022	BUY	$0.92 - $9.3 $263 - $2,659	286 Added 0.86%	33,352 $0
Q2 2022 May 14, 2024	BUY	$0.96 - $1.91 $31,743 - $63,156	33,066 New	33,066 $38,000
Q2 2022 Aug 15, 2022	SELL	$0.96 - $1.91 $1,926 - $3,833	-2,007 Reduced 5.72%	33,066 $38,000
Q1 2022 May 16, 2022	SELL	$1.6 - $3.35 $186,283 - $390,030	-116,427 Reduced 76.85%	35,073 $61,000
Q4 2021 Feb 14, 2022	BUY	$2.08 - $3.65 $315,120 - $552,975	151,500 New	151,500 $491,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $275M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.